Table 1.
Clinical trials of mRNA vaccines against infectious diseases beyond COVID-19
| Funding source | Name | Target | Vaccine type | Route of administration | Clinical trial phase | Clinical trial identifier |
|---|---|---|---|---|---|---|
| Moderna | mRNA-1647 | CMV | Nucleoside-modified mRNA–LNP | Intramuscular | Phase II | NCT04232280, NCT03382405 |
| Moderna | mRNA-1443 | CMV | Nucleoside-modified mRNA–LNP | Intramuscular | Phase I | NCT03382405 |
| Moderna | mRNA-1893 | Zika | Nucleoside-modified mRNA–LNP | Intramuscular | Phase I | NCT04064905 |
| Moderna | mRNA-1325 | Zika | Nucleoside-modified mRNA–LNP | Intramuscular | Phase I | NCT03014089 |
| Moderna | mRNA-1653 | hMPV/PIV3 | Nucleoside-modified mRNA–LNP | Intramuscular | Phase I | NCT04144348, NCT03392389 |
| Moderna | mRNA-1345 | RSV | Nucleoside-modified mRNA–LNP | Intramuscular | Phase I | NCT04528719 |
| Moderna, Merck | mRNA-1777 (V171) | RSV | Nucleoside-modified mRNA–LNP | Intramuscular | Phase I | Unregistered |
| Moderna, Merck | mRNA-1172 (V172) | RSV | Nucleoside-modified mRNA–LNP | Intramuscular | Phase I | Unregistered |
| Moderna | mRNA-1851 (VAL-339851) | Influenza A (H7N9) | Nucleoside-modified mRNA–LNP | Intramuscular | Phase I | NCT03345043 |
| Moderna | mRNA-1440 (VAL-506440) | Influenza A (H10N8) | Nucleoside-modified mRNA–LNP | Intramuscular | Phase I | NCT03076385 |
| Moderna | mRNA-1010 | Influenza A (H1N1, H3N2), influenza B (Yamagata lineage, Victoria lineage) | Unknown | Intramuscular | Phase I/II | NCT04956575 |
| Translate Bio, Sanofi | MRT5400 | Influenza A (H3N2) | Unknown | Intramuscular | Phase I | Unregistered |
| Translate Bio, Sanofi | MRT5401 | Influenza A (H3N2) | Unknown | Intramuscular | Phase I | Unregistered |
| Moderna | mRNA-1944 | Chikungunya | Nucleoside-modified mRNA–LNP | Intramuscular | Phase I | NCT03829384 |
| Moderna | mRNA-1388 (VAL-181388) | Chikungunya | Nucleoside-modified mRNA–LNP | Intramuscular | Phase I | NCT03325075 |
| CureVac | CV7201 | Rabies | Unmodified mRNA complexed in RNActive | Intradermal, intramuscular | Phase I | NCT02241135 |
| CureVac | CV7202 | Rabies | Unmodified mRNA–LNP | Intramuscular | Phase I | NCT03713086 |
| GSK | GSK3903133A | Rabies | Self-amplifying mRNA in cationic nanoemulsion | Intramuscular | Phase I | NCT04062669 |
CMV, cytomegalovirus; GSK, GlaxoSmithKline; HIV, human immunodeficiency virus; hMPV, human metapneumovirus; LNP, lipid nanoparticle; PIV3, parainfluenza virus type 3; RSV, respiratory syncytial virus.